<DOC>
	<DOCNO>NCT00327184</DOCNO>
	<brief_summary>The purpose primary vaccination phase demonstrate non-inferiority two dos Biologicals ' Hib-MenC conjugate vaccine give Infanrix™ penta infant ( 3 &amp; 5m ) compare NeisVac-C™ give Infanrix™ hexa . The purpose booster vaccination phase evaluate immunogenicity , safety reactogenicity booster dose Hib-MenC vaccine give Infanrix™ penta 11 age versus NeisVac-C™ give Infanrix™ hexa , well antibody persistence prior administration booster dos . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Primary &amp; Booster Study Infants Demonstrate Non-inferiority , Persistence &amp; Immunogenicity Hib-MenC Vaccine</brief_title>
	<detailed_description>This multicenter study open consist primary booster phase . The study 2 treatment group NeisVac-C™ + Infanrix™ hexa active control . In primary phase , one blood sample collect subject immunogenicity analyses- one month second vaccination dose . In booster phase , two blood sample collect : prior one month post booster vaccination .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Inclusion Criteria Primary Phase : Subjects investigator believe parents/guardians comply requirement protocol enrol study . healthy male female subject , include , 6 12 week age time first vaccination , born gestation period include 36 42 week . Written inform consent obtain parent guardian subject prior study entry . Free obvious health problem establish medical history clinical examination enter study . Booster Phase : • Participation primary phase study . Exclusion Criteria Primary Phase : Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) since birth plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . Planned administration/ administration vaccine foreseen study protocol since birth , exception BCG . Previous vaccination meningococcal serogroup C disease , diphtheria , tetanus , pertussis , polio , pneumococcal , Hepatitis B Hib disease History Haemophilus influenzae type b /or meningococcal serogroup C disease . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment . Administration immunoglobulins and/or blood product since birth plan administration study period . Additional Exclusion criterion Booster Phase : • Previous booster vaccination Hib and/or MenC and/or DTP contain and/or IPV contain and/or HepB contain vaccine ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>